Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Activists United and Ignited by Urgency for HIV Prevention in Europe: EATG and AVAC call for the rollout of PrEP as a proven HIV prevention strategy

Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.

Published
03 February 2016
From
EATG
Microbicide Development Hinges on New Products Administered in New Ways

Non-specific or antiretroviral-based vaginal gels failed to work but new formulations offer hope.

Published
11 January 2016
From
IAVI Report
Will Nutland: The emergence of the end of HIV

Will Nutland proposes that instead of the Hollywood style ‘end of AIDS moment’ fantasy, the end of AIDS will be a process with a number of emerging endpoints. In this eye-opening talk, Will introduces PrEP and rectal microbicides and discusses their efficacy and levels of acceptability. He surmises that the end might happen without us even noticing.

Published
10 November 2015
From
TEDx Talks / You Tube
Why Microbicides for HIV Prevention Are Still Necessary in the Treatment-as-Prevention Era

How do things stand with the development of topical agents for HIV prevention? In the age of oral pre-exposure prophylaxis (PrEP) and treatment as prevention, does it matter anymore? And if lessons learned by researchers in the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial -- discussed most often in terms of its failure -- help make future HIV clinical trials more effective, can we really call it a failure?

Published
02 November 2015
From
The Body Pro
Superhero Vaginal Bacteria Species Traps HIV, Could Be a Natural Condom Someday

The benevolent powers of the vaginal microbiome are even greater than we thought. In addition to aiding fertilization and protecting fetuses during pregnancy, healthy vaginal mucus that’s full of good bacteria can trap and immobilize HIV particles. The study examined the cervicovaginal mucus, or CVM, of 31 women and tested its ability to immobilize HIV particles. CVM samples that contained higher concentrations of D-lactic acid, which only bacteria can produce, did far better than others. The D-lactic acid wasn’t itself a barrier to HIV, but an indicator of something else going on that made certain types of CVM better at trapping the virus than others. That something was Lactobacillus crispatus, a species of bacteria that could change the way we think about HIV prevention.

Published
08 October 2015
From
Slate
ICAAC 2015: Combination Vaginal Ring May Be Able to Prevent Both HIV and Herpes

An experimental silicone vaginal ring with separate compartments may be able to deliver both tenofovir for prevention of HIV infection and acyclovir for prevention of genital herpes and potentially other sexually transmitted infections (STIs), according to a report at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego.

Published
28 September 2015
From
HIVandHepatitis.com
'HIV gel' effective against herpes

A microbicide gel initially intended to offer protection against HIV has been found to be effective against herpes. Herpes is one of the most common sexually transmitted diseases in South Africa. In the latest study, published in the New England Journal of Medicine, researchers from the Centre for the Aids Programme of Research in South Africa (Caprisa) showed that Tenofovir gel halved the risk of developing herpes simplex virus type 2 – a virus that is a leading cause of genital ulcers.

Published
13 August 2015
From
Independent Online (South Africa)
Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.

Published
19 July 2015
From
AVAC
Where next in PrEP and microbicides? Europeans discuss research pipeline

Thursday 18 June saw the final research meeting in Brussels of CHAARM (Combined Highly Active Anti-Retroviral Microbicides), the EU-supported research consortium which for the last five and a

Published
07 July 2015
By
Gus Cairns
Researchers complete ASPIRE Phase III trial of vaginal ring for HIV prevention in women

In a first for HIV prevention, researchers have completed follow-up of participants in a pivotal Phase III trial that tested a vaginal ring for preventing HIV in women. The ring, which contains the ARV dapivirine, is meant to be worn for a month at a time. More than 2,600 African women took part in ASPIRE, one of two Phase III trials designed to support potential licensure of the ring. Results are expected early 2016.

Published
29 June 2015
From
Eurekalert Medicine & Health

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.